Browse By: Country ι Category ι Latest Reports ι Tag
Home  »  Global Markets Direct

Global Markets Direct Market Research Reports

Global Markets Direct is a leading provider of global business intelligence and market analysis. The company publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials.

At the heart of Global Markets Direct are unique databases, updated live, covering millions of rows of key information for the studied industry at a global level.

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016’, provides in depth analysis on Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted pipeline therapeutics. The report provides comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF-8), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8)
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016’, provides in depth analysis on CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted pipeline therapeutics. The report provides comprehensive information on the CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the des
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Pipeline Review, H1 2016’, provides in depth analysis on C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) targeted pipeline therapeutics. The report provides comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development histo
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Apolipoprotein E (ApoE) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Apolipoprotein E (ApoE) - Pipeline Review, H1 2016’, provides in depth analysis on Apolipoprotein E (ApoE) targeted pipeline therapeutics. The report provides comprehensive information on the Apolipoprotein E (ApoE) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Apolipoprotein E (ApoE) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct’s report
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Catenin Beta-1 (Beta Catenin or CTNNB1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Catenin Beta-1 (Beta Catenin or CTNNB1) - Pipeline Review, H1 2016’, provides in depth analysis on Catenin Beta-1 (Beta Catenin or CTNNB1) targeted pipeline therapeutics. The report provides comprehensive information on the Catenin Beta-1 (Beta Catenin or CTNNB1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Catenin Beta-1 (Beta Catenin or CTNNB1) targeted therapeutics development and features dorma
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016’, provides in depth analysis on C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted pipeline therapeutics. The report provides comprehensive information on the C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4), targeted t
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016’, provides in depth analysis on Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted pipeline therapeutics. The report provides comprehensive information on the Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H1 2016’, provides in depth analysis on Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted pipeline therapeutics. The report provides comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players in
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016’, provides in depth analysis on Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information on the Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecu
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016’, provides in depth analysis on Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted pipeline therapeutics. The report provides comprehensive information on the Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30), targeted therapeutics, complete with analysis by indications, stage o
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Pipeline Review, H1 2016’, provides in depth analysis on Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted pipeline therapeutics. The report provides comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and la
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016’, provides in depth analysis on Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted pipeline therapeutics. The report provides comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additiona
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Pipeline Review, H1 2016’, provides in depth analysis on Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted pipeline therapeutics. The report provides comprehensive information on the Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin B (APP Secretase or Cathe
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H1 2016’, provides in depth analysis on Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted pipeline therapeutics. The report provides comprehensive information on the Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete res
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Gamma Secretase (EC 3.4.23.46) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Gamma Secretase (EC 3.4.23.46) - Pipeline Review, H1 2016’, provides in depth analysis on Gamma Secretase (EC 3.4.23.46) targeted pipeline therapeutics. The report provides comprehensive information on the Gamma Secretase (EC 3.4.23.46), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Gamma Secretase (EC 3.4.23.46) targeted therapeutics development and features dormant and discontinued projects. Globa
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
20s Proteasome - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘20s Proteasome - Pipeline Review, H1 2016’, provides in depth analysis on 20s Proteasome targeted pipeline therapeutics. The report provides comprehensive information on the 20s Proteasome , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 20s Proteasome targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Pipeline Review, H1 2016’, provides in depth analysis on P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) targeted pipeline therapeutics. The report provides comprehensive information on the P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2016’, provides in depth analysis on Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted pipeline therapeutics. The report provides comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacologi
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Pipeline Review, H1 2016’, provides in depth analysis on Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) targeted pipeline therapeutics. The report provides comprehensive information on the Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glycogen Synthase Kinase 3 Be
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2016’, provides in depth analysis on Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, m
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016’, provides in depth analysis on Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted pipeline therapeutics. The report provides comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players invol
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016’, provides in depth analysis on Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted pipeline therapeutics. The report provides comprehensive information on the Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descripti
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016’, provides in depth analysis on Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted pipeline therapeutics. The report provides comprehensive information on the Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Advinus Therapeutics Ltd - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Advinus Therapeutics Ltd - Product Pipeline Review - 2016’, provides an overview of the Advinus Therapeutics Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Advinus Therapeutics Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2016’, provides an overview of the BioMarin Pharmaceutical Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by BioMarin Pharmaceutical Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
La Jolla Pharmaceutical Company - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘La Jolla Pharmaceutical Company - Product Pipeline Review - 2016’, provides an overview of the La Jolla Pharmaceutical Company’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by La Jolla Pharmaceutical Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
Pfenex Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Pfenex Inc. - Product Pipeline Review - 2016’, provides an overview of the Pfenex Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Pfenex Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Glob
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
XOMA Corporation - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘XOMA Corporation - Product Pipeline Review - 2016’, provides an overview of the XOMA Corporation’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by XOMA Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information so
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016’, provides an overview of the Glioblastoma Multiforme (GBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. Global Markets D
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2500
Liver Cancer - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Liver Cancer - Pipeline Review, H1 2016’, provides an overview of the Liver Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liver Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe co
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2500
Acute Lung Injury - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Acute Lung Injury - Pipeline Review, H1 2016’, provides an overview of the Acute Lung Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Lung Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Lung Injury and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016’, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and featur
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Burkholderia Infections - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Burkholderia Infections - Pipeline Review, H1 2016’, provides an overview of the Burkholderia Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Burkholderia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkholderia Infections and features dormant and discontinued projects. Global Markets Direct’s report feature
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Progressive Supranuclear Palsy - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Progressive Supranuclear Palsy - Pipeline Review, H1 2016’, provides an overview of the Progressive Supranuclear Palsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. Global Mark
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016’, provides in depth analysis on Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted pipeline therapeutics. The report provides comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of k
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Pipeline Review, H1 2016’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted pipeline therapeutics. The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development histo
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2016’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) targeted pipeline therapeutics. The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The repor
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Pipeline Review, H1 2016’, provides in depth analysis on Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted pipeline therapeutics. The report provides comprehensive information on the Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Glycoprotein 41 (gp41) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Glycoprotein 41 (gp41) - Pipeline Review, H1 2016’, provides in depth analysis on Glycoprotein 41 (gp41) targeted pipeline therapeutics. The report provides comprehensive information on the Glycoprotein 41 (gp41), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glycoprotein 41 (gp41) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct’s report feat
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Pipeline Review, H1 2016’, provides in depth analysis on Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted pipeline therapeutics. The report provides comprehensive information on the Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an ov
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Pipeline Review, H1 2016’, provides in depth analysis on Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted pipeline therapeutics. The report provides comprehensive information on the Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Protein Kinase C Epsilon Type
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2016’, provides in depth analysis on C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted pipeline therapeutics. The report provides comprehensive information on the C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press rele
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H1 2016’, provides in depth analysis on C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) targeted pipeline therapeutics. The report provides comprehensive information on the C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The repor
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Pipeline Review, H1 2016’, provides in depth analysis on Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted pipeline therapeutics. The report provides comprehensive information on the Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) - Pipeline Review, H1 2016’, provides in depth analysis on Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted pipeline therapeutics. The report provides comprehensive information on the Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Pipeline Review, H1 2016’, provides in depth analysis on Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted pipeline therapeutics. The report provides comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1), targeted therapeutics, complete with ana
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H1 2016’, provides in depth analysis on Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) targeted pipeline therapeutics. The report provides comprehensive information on the Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146), targeted ther
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) - Pipeline Review, H1 2016’, provides in depth analysis on Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) targeted pipeline therapeutics. The report provides comprehensive information on the Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The repor
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Histone Deacetylase 1 (EC 3.5.1.98) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Histone Deacetylase 1 (EC 3.5.1.98) - Pipeline Review, H1 2016’, provides in depth analysis on Histone Deacetylase 1 (EC 3.5.1.98) targeted pipeline therapeutics. The report provides comprehensive information on the Histone Deacetylase 1 (EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 1 (EC 3.5.1.98) targeted therapeutics development and features dormant and discontin
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Cathepsin S (EC 3.4.22.27) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Cathepsin S (EC 3.4.22.27) - Pipeline Review, H1 2016’, provides in depth analysis on Cathepsin S (EC 3.4.22.27) targeted pipeline therapeutics. The report provides comprehensive information on the Cathepsin S (EC 3.4.22.27), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin S (EC 3.4.22.27) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Cathepsin L (EC 3.4.22.15) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Cathepsin L (EC 3.4.22.15) - Pipeline Review, H1 2016’, provides in depth analysis on Cathepsin L (EC 3.4.22.15) targeted pipeline therapeutics. The report provides comprehensive information on the Cathepsin L (EC 3.4.22.15), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin L (EC 3.4.22.15) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2016’, provides in depth analysis on Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.) targeted pipeline therapeutics. The report provides comprehensive information on the Collagenase 3 (Matrix Metalloproteinase-13 or MMP13 or EC 3.4.24.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Collagenase
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H1 2016’, provides in depth analysis on Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in I
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $3500
CytomX Therapeutics, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘CytomX Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the CytomX Therapeutics, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by CytomX Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built us
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
Kuhnil Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Kuhnil Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Kuhnil Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Kuhnil Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
TechnoPhage SA - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘TechnoPhage SA - Product Pipeline Review - 2016’, provides an overview of the TechnoPhage SA’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by TechnoPhage SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
Multiple Sclerosis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Multiple Sclerosis - Pipeline Review, H1 2016’, provides an overview of the Multiple Sclerosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Multiple Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. Global Markets Direct’s report features investigational dr
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2500
Colon Cancer - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Colon Cancer - Pipeline Review, H1 2016’, provides an overview of the Colon Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colon Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe co
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2500
Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2016’, provides an overview of the Multiple Myeloma (Kahler Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects.
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2500
Dengue Fever - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Dengue Fever - Pipeline Review, H1 2016’, provides an overview of the Dengue Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dengue Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe co
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Bacterial Pneumonia - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Bacterial Pneumonia - Pipeline Review, H1 2016’, provides an overview of the Bacterial Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bacterial Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Pneumonia and features dormant and discontinued projects. Global Markets Direct’s report features investigationa
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Pertussis (Whooping Cough) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Pertussis (Whooping Cough) - Pipeline Review, H1 2016’, provides an overview of the Pertussis (Whooping Cough) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pertussis (Whooping Cough) and features dormant and discontinued projects. Global Markets Direct’s re
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2016’, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal An
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline Review, H1 2016’, provides an overview of the Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sys
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Hypertriglyceridemia - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Hypertriglyceridemia - Pipeline Review, H1 2016’, provides an overview of the Hypertriglyceridemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypertriglyceridemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued projects. Global Markets Direct’s report features investigat
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Smoking Addiction - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Smoking Addiction - Pipeline Review, H1 2016’, provides an overview of the Smoking Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Smoking Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smoking Addiction and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Streptococcal Infections - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Streptococcal Infections - Pipeline Review, H1 2016’, provides an overview of the Streptococcal Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Streptococcal Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Streptococcal Infections and features dormant and discontinued projects. Global Markets Direct’s report fea
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Rhino-Conjunctivitis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Rhino-Conjunctivitis - Pipeline Review, H1 2016’, provides an overview of the Rhino-Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. Global Markets Direct’s report features investigat
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Gaucher Disease - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Gaucher Disease - Pipeline Review, H1 2016’, provides an overview of the Gaucher Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gaucher Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gaucher Disease and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from acr
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Female Contraception - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Female Contraception - Pipeline Review, H1 2016’, provides an overview of the Female Contraception pipeline landscape. The report provides comprehensive information on the therapeutics under development for Female Contraception, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. Global Markets Direct’s report features investigat
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Peptic Ulcers - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Peptic Ulcers - Pipeline Review, H1 2016’, provides an overview of the Peptic Ulcers pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peptic Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across glob
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Neurofibromatoses - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Neurofibromatoses - Pipeline Review, H1 2016’, provides an overview of the Neurofibromatoses pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neurofibromatoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neurofibromatoses and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Lassa Fever - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Lassa Fever - Pipeline Review, H1 2016’, provides an overview of the Lassa Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lassa Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lassa Fever and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe coveri
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2016’, provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mucopolysaccharidosis II (M
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2016’, provides an overview of the Systemic Idiopathic Juvenile Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic Idiopathic Juvenile Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Idiopathic Juvenile Arthritis and features dormant and disco
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Female Sexual Dysfunction - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Female Sexual Dysfunction - Pipeline Review, H1 2016’, provides an overview of the Female Sexual Dysfunction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. Global Markets Direct’s report
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Wegener Polyangiitis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Wegener Polyangiitis - Pipeline Review, H1 2016’, provides an overview of the Wegener Polyangiitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Wegener Polyangiitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wegener Polyangiitis and features dormant and discontinued projects. Global Markets Direct’s report features investigat
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Meningitis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Meningitis - Pipeline Review, H1 2016’, provides an overview of the Meningitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering o
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Ignyta, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Ignyta, Inc. - Product Pipeline Review - 2016’, provides an overview of the Ignyta, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Ignyta, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from G
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
Nanotherapeutics, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Nanotherapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Nanotherapeutics, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Nanotherapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
Sangamo BioSciences, Inc. - Product Pipeline Review - 2016
Summary Global Markets Direct’s, ‘Sangamo BioSciences, Inc. - Product Pipeline Review - 2016’, provides an overview of the Sangamo BioSciences, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Sangamo BioSciences, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built us
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $1500
Type 1 diabetes (Juvenile Diabetes) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2016’, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued proj
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Hypertension - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Hypertension - Pipeline Review, H1 2016’, provides an overview of the Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe co
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016’, provides an overview of the Kidney Cancer (Renal Cell Cancer) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects.
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2500
Streptococcal Pneumonia - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Streptococcal Pneumonia - Pipeline Review, H1 2016’, provides an overview of the Streptococcal Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Streptococcal Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Streptococcal Pneumonia and features dormant and discontinued projects. Global Markets Direct’s report feature
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016’, provides an overview of the Herpes Simplex Virus (HSV) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Herpes Simplex Virus (HSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Simplex Virus (HSV) Infections and features dormant and discontin
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016’, provides an overview of the Retinitis Pigmentosa (Retinitis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. Glob
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2016’, provides an overview of the Liver Failure (Hepatic Insufficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontin
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Poliomyelitis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Poliomyelitis - Pipeline Review, H1 2016’, provides an overview of the Poliomyelitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Poliomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across glob
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016’, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in the
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2016’, provides an overview of the Pituitary ACTH Hypersecretion (Cushing Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Dis
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Retinopathy - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Retinopathy - Pipeline Review, H1 2016’, provides an overview of the Retinopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinopathy and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe coveri
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Myocardial Fibrosis - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Myocardial Fibrosis - Pipeline Review, H1 2016’, provides an overview of the Myocardial Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myocardial Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. Global Markets Direct’s report features investigationa
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Sicca Syndrome (Sjogren) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Sicca Syndrome (Sjogren) - Pipeline Review, H1 2016’, provides an overview of the Sicca Syndrome (Sjogren) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. Global Markets Direct’s report fea
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H1 2016’, provides an overview of the Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mucopolysaccha
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Medulloblastoma - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Medulloblastoma - Pipeline Review, H1 2016’, provides an overview of the Medulloblastoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Medulloblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from acr
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H1 2016’, provides an overview of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurle
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H1 2016’, provides an overview of the Vasomotor Symptoms of Menopause (Hot Flashes) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vasomotor Symptoms of Menopause (Hot Flashes) an
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Hyperglycemia - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Hyperglycemia - Pipeline Review, H1 2016’, provides an overview of the Hyperglycemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperglycemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperglycemia and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across glob
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000
Encephalopathy - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Encephalopathy - Pipeline Review, H1 2016’, provides an overview of the Encephalopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2000